COMPANY
AstraZeneca
“We are a global, science-led, patient-focused pharmaceutical business. We are committed to excellence in the research, development and commercialisation of prescription medicines.” Source · checked Oct 13, 2026
Job board
1,287 open jobs in Radar’s scan (jobs updated Oct 23, 2026). Source: astrazeneca.wd3.myworkdayjobs.com (board matched by name; a link from the company site was not found yet). Counts come from Radar’s own daily scan of this board, not from the company.
Sourced facts
Therapeutic areas or services
- We deliver a diversified portfolio of medicines across primary care, specialty care and rare diseases through our broad-based global network. · astrazeneca.com · checked Oct 13, 2026
Focus / stage (company wording)
- primary care, specialty care and rare diseases · astrazeneca.com · checked Oct 13, 2026
Headquarters address
- Cambridge Biomedical Campus, Cambridge, United Kingdom · sec.gov · checked Oct 13, 2026
- · sec.gov · checked Oct 13, 2026
FDA (example approval)
- Imfinzi · purplebooksearch.fda.gov · checked Oct 13, 2026
Open jobs 1,287
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Therapy Area Specialist / Pharmareferent (m/w/d) Respiratory (COPD) Gebiet: Konstanz, Villingen-Schwenningen, Göppingen, Heilbronn, Tübingen, Reutlingen | 2 locations, including Hamburg, Germany | Oct 21, 2026 | Oct 12, 2026 |
| Therapy Area Specialist / Pharmareferent (m/w/d) Respiratory (COPD) Gebiet: Ingolstadt, Regensburg, Passau, Rosenheim | 2 locations, including Hamburg, Germany | Oct 21, 2026 | Oct 12, 2026 |
| Therapy Area Specialist / Pharmareferent (m/w/d) Respiratory (COPD) Gebiet: München, Garmisch-Partenkirchen, Kempten, Augsburg | 2 locations, including Hamburg, Germany | Oct 21, 2026 | Oct 12, 2026 |
| Electronic Batch Record Specialist | Singapore | Oct 21, 2026 | Oct 15, 2026 |
| Senior Software Engineer, AI-Native Development - Evinova | Spain - Barcelona | Oct 21, 2026 | Oct 15, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 3 trial (NCT07816666, actual start Sep 24, 2026) (+23 other new trials); 85 clinical-operations roles open. ClinicalTrials.gov NCT07816666 (Sep 24, 2026)
Evidence (24 events)
- Sep 24, 2026 · ClinicalTrials.gov NCT07816666
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-24,type:ACTUAL}; studyFirstPostDate=2026-09-14; briefTitle='Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer' - Sep 17, 2026 · ClinicalTrials.gov NCT07686120
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-07-07; briefTitle='A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.' - Sep 16, 2026 · ClinicalTrials.gov NCT07851025
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-16,type:ACTUAL}; studyFirstPostDate=2026-10-01; briefTitle='Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial O' - Sep 15, 2026 · ClinicalTrials.gov NCT07711002
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-15,type:ACTUAL}; studyFirstPostDate=2026-07-17; briefTitle="Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy With" - Sep 10, 2026 · ClinicalTrials.gov NCT07619118
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-10,type:ACTUAL}; studyFirstPostDate=2026-06-01; briefTitle='A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholestero' - Sep 1, 2026 · ClinicalTrials.gov NCT07624305
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-01,type:ACTUAL}; studyFirstPostDate=2026-06-03; briefTitle='A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)' - Aug 31, 2026 · ClinicalTrials.gov NCT07751848
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-08-07; briefTitle='A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus' - Aug 31, 2026 · ClinicalTrials.gov NCT07691970
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-07-09; briefTitle='Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Conti' - Aug 24, 2026 · ClinicalTrials.gov NCT07776509
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight' - Aug 24, 2026 · ClinicalTrials.gov NCT07761117
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-08-12; briefTitle='A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF' - Aug 21, 2026 · ClinicalTrials.gov NCT07753993
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-21,type:ACTUAL}; studyFirstPostDate=2026-08-10; briefTitle='A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.' - Aug 21, 2026 · ClinicalTrials.gov NCT07775404
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-21,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabe' - Aug 20, 2026 · ClinicalTrials.gov NCT07784270
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-20,type:ACTUAL}; studyFirstPostDate=2026-08-25; briefTitle='A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight' - Aug 19, 2026 · ClinicalTrials.gov NCT07784725
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-19,type:ACTUAL}; studyFirstPostDate=2026-08-25; briefTitle='A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabet' - Aug 12, 2026 · ClinicalTrials.gov NCT07619131
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-12,type:ACTUAL}; studyFirstPostDate=2026-06-01; briefTitle='A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT' - Jul 24, 2026 · ClinicalTrials.gov NCT07444567
leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-24,type:ACTUAL}; studyFirstPostDate=2026-03-03; briefTitle='Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatme' - Aug 31, 2026 · ClinicalTrials.gov NCT07630714
leadSponsor.name='AstraZeneca'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-06-05; briefTitle='A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years ' - Jul 27, 2026 · ClinicalTrials.gov NCT07681596
leadSponsor.name='AstraZeneca'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-07-02; briefTitle='A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma' - Aug 31, 2026 · ClinicalTrials.gov NCT07824622
leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-09-17; briefTitle='Study of Safety and PK of AZD0543 in Healthy Adults' - Aug 6, 2026 · ClinicalTrials.gov NCT07754331
leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-06,type:ACTUAL}; studyFirstPostDate=2026-08-10; briefTitle='Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin' - Jul 30, 2026 · ClinicalTrials.gov NCT07685600
leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-07-06; briefTitle='Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants' - Jul 27, 2026 · ClinicalTrials.gov NCT07723833
leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-07-23; briefTitle='A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants' - Jul 23, 2026 · ClinicalTrials.gov NCT06951880
leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-23,type:ACTUAL}; studyFirstPostDate=2025-04-30; briefTitle='A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers' - Sep 5, 2026 · ClinicalTrials.gov NCT07718724
leadSponsor.name='AstraZeneca'; phases=['NA']; overallStatus=RECRUITING; startDateStruct={date:2026-09-05,type:ACTUAL}; studyFirstPostDate=2026-07-22; briefTitle='Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist'
- Sep 24, 2026 · ClinicalTrials.gov NCT07816666
- Drug approval + hiring FDA novel approval for ETCAMAH (NDA 220359, Sep 4, 2026; +3 other approvals); 605 manufacturing/quality or commercial roles open. FDA NDA 220359 (Sep 4, 2026)
Evidence (4 events)
- Sep 4, 2026 · FDA NDA 220359
openFDA drugsfda: application_number=NDA220359; sponsor_name='ASTRAZENECA'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260904; submission_class_code=TYPE 1; brand_name=['ETCAMAH'] - May 15, 2026 · FDA NDA 219878
openFDA drugsfda: application_number=NDA219878; sponsor_name='ASTRAZENECA AB'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260515; submission_class_code=TYPE 1; brand_name=['BAXFENDY'] - Oct 8, 2026 · FDA NDA 220290
openFDA drugsfda: application_number=NDA220290; sponsor_name='ASTRAZENECA AB'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20261008; submission_class_code=TYPE 5; brand_name=['BREZTRI AEROSPHERE'] - Apr 24, 2026 · FDA BLA 761451
openFDA drugsfda: application_number=BLA761451; sponsor_name='ASTRAZENECA AB'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260424; submission_class_code=TYPE 5; brand_name=['SAPHNELO']
- Sep 4, 2026 · FDA NDA 220359